Premixed Insulins (70/30, 50/50) Injectable bulk supplier for pharma manufacturers

Premixed Insulins (70/30, 50/50) Injectable Suppliers & Bulk Manufacturers

Available Forms: Vials, pens

Available Strengths: U-100

Reference Brands: Humulin, Novolin(US); Mixtard, Humulin, Insuman(EU)

Category: Diabetes

Premixed Insulins (70/30, 50/50) Injectable is available in Vials, pens and strengths such as U-100. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Premixed Insulins (70/30, 50/50) Injectable is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Premixed Insulins (70/30, 50/50) Injectable can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Product Description:

Premixed insulins (70/30, 50/50) are regulated in the EU and US as combination biological medicines. In the EU, brands like Mixtard and Humulin 70/30 are approved by EMA based on comprehensive dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, the FDA has approved products like Humulin 70/30 and Novolin 70/30, supported by detailed clinical data and biosimilarity assessments, with ongoing pharmacovigilance. Both regions require robust regulatory dossiers for approval and post-marketing safety. For expert support with pharmaceutical dossiers and compliance, visit PharmaTradz, your trusted partner in regulatory solutions.

Frequently Asked Questions

Yes, Premixed Insulins (70/30, 50/50) Injectable is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Premixed Insulins (70/30, 50/50) Injectable is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Insulin Lispro (Humalog) Injectable

Strength: U-100, U-200

Form: Vials/pens

Reference Brands: Humalog, Admelog, Fiasp(US); Humalog, Fiasp(EU)

View Details
Insulin Aspart (Novolog) Injectable

Strength: U-100, U-200

Form: Vials/pens

Reference Brands: Novolog, Fiasp(US &EU)

View Details
Insulin Glargine (Lantus) Injectable

Strength: U-100, U-300

Form: Vials/pens

Reference Brands: Lantus, Basaglar, Toujeo(US); Lantus, Toujeo(EU)

View Details
Regular Insulin (Human) Injectable

Strength: U-100 (100 units/mL)

Form: Vials/pens

Reference Brands: Humulin R, Novolin R, Admelog R(US); Actrapid, Humulin R, Monotard R(EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.